Anandi N Sheth1, Christine D Angert2, Lisa B Haddad3, C Christina Mehta4, Susan E Cohn5. 1. Department of Medicine, Emory University School of Medicine, Atlanta, GA, United States. Electronic address: ansheth@emory.edu. 2. Department of Medicine, Emory University School of Medicine, Atlanta, GA, United States. 3. Center for Biomedical Research, Population Council, New York, NY, United States. 4. Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, GA, United States. 5. Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, United States.
Abstract
OBJECTIVE(S): We describe contraception and dual method use among women with HIV initiating antiretroviral therapy (ART) in a U.S. clinical trial and examine associated factors. STUDY DESIGN: We analyzed data from ART-naïve women aged 45 years and under initiating one of 3 regimens as part of A5257 (May 2009-June 2011) which required that women at risk for pregnancy use contraception. We classified self-reported methods as more effective (Tier 1 [intrauterine device, hysterectomy, permanent contraception] and Tier 2 [hormonal rings, patches, injections, pills]) versus less effective (Tier 3 [condoms alone] and Tier 4 [withdrawal, none]). We used logistic regression models to assess associations with use of (a) more effective, and (b) dual methods (condoms with a more effective method). RESULTS: Of 285 women, majority were Black (59%), had annual income <$20,000 (54%), and had government insurance (68%). The most common contraceptive methods reported at baseline were permanent contraception (37%), male condoms alone (31%), and injectable progestin (8%); 41% and 16% reported Tier 1 and 2 use, respectively; 36% reported dual method use. Use of more effective and dual methods did not change 48 and 96 weeks after ART initiation (p > 0.05). In multivariable analyses, baseline use of more effective and dual methods was associated with age at least 40 years versus 18 to 29 years (odds ratio [OR] 4.46, 95% confidence interval [CI] 2.12, 9.35) and having at least one child (OR 2.31, 95%CI 1.27, 4.20). CONCLUSIONS: In women initiating modern ART in a clinical trial, permanent contraception was common, while use of other more effective contraceptive methods was low and did not change after ART initiation. Efforts are needed to improve integration of family planning services for women within the context of HIV clinical trials. IMPLICATIONS: The findings highlight the importance of improving integration of HIV and family planning services, including in the context of clinical trials.
OBJECTIVE(S): We describe contraception and dual method use among women with HIV initiating antiretroviral therapy (ART) in a U.S. clinical trial and examine associated factors. STUDY DESIGN: We analyzed data from ART-naïve women aged 45 years and under initiating one of 3 regimens as part of A5257 (May 2009-June 2011) which required that women at risk for pregnancy use contraception. We classified self-reported methods as more effective (Tier 1 [intrauterine device, hysterectomy, permanent contraception] and Tier 2 [hormonal rings, patches, injections, pills]) versus less effective (Tier 3 [condoms alone] and Tier 4 [withdrawal, none]). We used logistic regression models to assess associations with use of (a) more effective, and (b) dual methods (condoms with a more effective method). RESULTS: Of 285 women, majority were Black (59%), had annual income <$20,000 (54%), and had government insurance (68%). The most common contraceptive methods reported at baseline were permanent contraception (37%), male condoms alone (31%), and injectable progestin (8%); 41% and 16% reported Tier 1 and 2 use, respectively; 36% reported dual method use. Use of more effective and dual methods did not change 48 and 96 weeks after ART initiation (p > 0.05). In multivariable analyses, baseline use of more effective and dual methods was associated with age at least 40 years versus 18 to 29 years (odds ratio [OR] 4.46, 95% confidence interval [CI] 2.12, 9.35) and having at least one child (OR 2.31, 95%CI 1.27, 4.20). CONCLUSIONS: In women initiating modern ART in a clinical trial, permanent contraception was common, while use of other more effective contraceptive methods was low and did not change after ART initiation. Efforts are needed to improve integration of family planning services for women within the context of HIV clinical trials. IMPLICATIONS: The findings highlight the importance of improving integration of HIV and family planning services, including in the context of clinical trials.
Authors: Karine Dubé; Lara Hosey; Kate Starr; Liz Barr; David Evans; Erin Hoffman; Danielle M Campbell; Jane Simoni; Jeremy Sugarman; John Sauceda; Brandon Brown; Karen L Diepstra; Catherine Godfrey; Daniel R Kuritzkes; David A Wohl; Rajesh Gandhi; Eileen Scully Journal: AIDS Res Hum Retroviruses Date: 2020-04 Impact factor: 2.205
Authors: Jeffrey L Lennox; Raphael J Landovitz; Heather J Ribaudo; Ighovwerha Ofotokun; Lumine H Na; Catherine Godfrey; Daniel R Kuritzkes; Manish Sagar; Todd T Brown; Susan E Cohn; Grace A McComsey; Francesca Aweeka; Carl J Fichtenbaum; Rachel M Presti; Susan L Koletar; David W Haas; Kristine B Patterson; Constance A Benson; Bryan P Baugh; Randi Y Leavitt; James F Rooney; Daniel Seekins; Judith S Currier Journal: Ann Intern Med Date: 2014-10-07 Impact factor: 25.391
Authors: Martina L Badell; Eva Lathrop; Lisa B Haddad; Peggy Goedken; Minh Ly Nguyen; Carrie A Cwiak Journal: Infect Dis Obstet Gynecol Date: 2012-06-13
Authors: Kavita Nanda; Gretchen S Stuart; Jennifer Robinson; Andrew L Gray; Naomi K Tepper; Mary E Gaffield Journal: AIDS Date: 2017-04-24 Impact factor: 4.177
Authors: Kristen A Sullivan; Margaret Olivia Little; Nora E Rosenberg; Chifundo Zimba; Elana Jaffe; Sappho Gilbert; Jenell S Coleman; Irving Hoffman; Tiwonge Mtande; Jean Anderson; Marielle S Gross; Lisa Rahangdale; Ruth Faden; Anne Drapkin Lyerly Journal: PLoS One Date: 2019-05-08 Impact factor: 3.240